 |
인쇄하기
취소
|
KFDA approved Yuhan's anti-peptic drug Revanex tab.
Yuhan said that as of Sept. 15 the new drug named Revanex (Revaprazan) has been completely registered to the KFDA as an anti-duodenal ulcer drug, which will be of No. 9 of Korean new drug.
Revanex has been developed at about 40 billion won of investment since 1994. It's application for the KFDA approval was filed in Feb. this year with clinical data showing its profile of safety and efficacy...
Revanex has been developed at about 40 billion won of investment since 1994. It's application for the KFDA approval was filed in Feb. this year with clinical data showing its profile of safety and efficacy...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.